Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) [Phase 2, Phase 3]

View source ↗

Summary

This document provides a clinical trial update on the Phase 2/Phase 3 study evaluating Mitapivat (AG-348) in participants with Sickle Cell Disease, noting that …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Mitapivat (mitapivat)

Snippet

Sponsor: Agios Pharmaceuticals, Inc. | Conditions: Sickle Cell Disease | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING